Email Alert | RSS

Journal of Peking University(Health Sciences) ›› 2019, Vol. 51 ›› Issue (1): 49-52. doi: 10.19723/j.issn.1671-167X.2019.01.009

Previous Articles     Next Articles

Study of surgery combined with 125I brachytherapy for adenoid cystic carcinoma of oral and maxillofacial region

Cong LI,Shu-ming LIU,Lei ZHENG,Ming-wei HUANG,Yan SHI,Xiao-ming LV,Jian-guo ZHANG,Jie ZHANG()   

  1. Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Clinical Research Center for Oral Diseases & National Engineering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China
  • Received:2018-10-11 Online:2019-02-18 Published:2019-02-26
  • Contact: Jie ZHANG E-mail:zhangjie06@126.com

RICH HTML

   

PDF (PC)

Abstract:

Objective: To retrospectively analyze the results of treatment outcome by surgery combined with 125I brachytherapy and correlative factors of adenoid cystic carcinoma (ACC). Methods: In the study, 75 patients with primary ACC of oral and maxillofacial region were treated by surgery combined with 125I seeds brachytherapy. Radical resection or subtotal resection was applied for the tumor. The brachytherapy treatment planning system was used to create implant plans with the prescribed dose of 60 Gy to 120 Gy. The 125I seeds were implanted intraoperatively or postoperatively. The regular follow-up was required. The Kaplan-Meier method was used to assess the tumor control rate and the patients’ survival rates. Meanwhile, the Cox regression analysis was used to find out the prognostic factors. Results: Local control rates at the end of 3 and 5 years were as follows: T1-T2, 92.2% and 82.0%; T3-T4, 82.6% and 82.6%; and overall, 90.0% and 78.8%. The disease-free survival rates were 74.9% and 54.3%, respectively. The overall survival rates for all the patients were 86.0% and 79.6%, respectively at the end of 3 and 5 years and were 91.3% and 91.3% for T1-T2 patients vs. 73.9% and 59.7% for T3-T4 patients. Distant metastasis-free survival rates at the end of 3 and 5 years were 84.4% and 76.7%, respectively. The distant metastasis-free survival rates at the end of 3 and 5 years were 83.4% and 79.6% with T1-T2 lesion compared with 86.0% and 67.8% with T3-T4 lesion. According to the COX univariate analysis and multivariate analysis, the risk of local recurrence would be raised by the age. Tumor stage and tumor site were the prognostic factors of the overall survival rates. Conclusion: 125I brachytherapy conducted as an adjuvant therapy postoperatively of ACC of oral and maxillofacial region can acquire satisfactory local-regional control, distant metastasis-free survival, disease-free survival and overall survival. Tumors are prone to recur on the older patients. Patients having advanced tumor stage or tumor located in the nasal cavity or sinuses will suffer lower survival rates.

Key words: Carcinoma, adenoid cystic, Mouth neoplasms, Brachytherapy, Iodine radioisotopes, Prognosis

CLC Number: 

  • R739.8

Table 1

Characteristics of 75 patients with ACC"

Items Data
Gender,n (%)
Male 21 (28)
Female 54 (72)
Age/years, median (range) 48.0 (18-74)
Follow-up time/months, median (range) 46.8 (0.4-111.0)
Tumor site,n (%)
Parotid glands 24 (32.0)
Submandibular glands 13 (17.3)
Sublingual glands 7 (9.3)
Palate 11 (14.7)
Mouth floor 11 (14.7)
Cheek 2 (2.7)
Tongue 3 (4.0)
Parapharyngeal 1 (1.3)
Other 3 (4.0)
T stage,n (%)
T1 22 (29.3)
T2 19 (25.3)
T3 2 (2.7)
T4 23 (30.7)
Not reported 9 (12.0)
N stage,n (%)
N0 64 (85.3)
N1 3 (4.0)
Not reported 8 (10.7)
Surgical margins,n (%)
Positive 14 (18.7)
Clear 61(81.3)
[1] Kokemueller H, Eckardt A, Brachvogel P , et al. Adenoid cystic carcinoma of the head and neck: a 20 years experience[J]. Int J Oral Maxillofac Surg, 2004,33(1):25-31.
doi: 10.1054/ijom.2003.0448 pmid: 14690656
[2] Zhang CY, Xia RH, Han J , et al. Adenoid cystic carcinoma of the head and neck: clinicopathologic analysis of 218 cases in a Chinese population[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013,115(3):368-375.
doi: 10.1016/j.oooo.2012.11.018 pmid: 23453028
[3] Tian Z, Li L, Wang L , et al. Salivary gland neoplasms in oral and maxillofacial regions: a 23-year retrospective study of 6 982 cases in an eastern Chinese population[J]. Int J Oral Maxillofac Surg, 2010,39(3):235-242.
doi: 10.1016/j.ijom.2009.10.016 pmid: 19951834
[4] 于世凤, 高岩 . 口腔组织学与病理学[M]. 北京: 北京大学医学出版社, 2005: 307.
[5] Maciejewski A, Szymczyk C, Wierzgon J . Outcome of surgery for adenoid cystic carcinoma of head and neck region[J]. J Craniomaxillofac Surg, 2002,30(1):59-61.
doi: 10.1054/jcms.2001.0265 pmid: 12064885
[6] Garden AS, Weber RS, Morrison WH , et al. The influence of positive margins and nerve invasion in adenoid cystic carcinoma of the head and neck treated with surgery and radiation[J]. Int J Radiat Oncol Biol Phys, 1995,32(3):619-626.
doi: 10.1016/0360-3016(95)00122-F pmid: 7790247
[7] Mendenhall WM, Morris CG, Amdur RJ , et al. Radiotherapy alone or combined with surgery for adenoid cystic carcinoma of the head and neck[J]. Head Neck, 2004,26(2):154-162.
doi: 10.1002/hed.10380 pmid: 14762884
[8] Huang MW, Zheng L, Liu SM , et al. 125I brachytherapy alone for recurrent or locally advanced adenoid cystic carcinoma of the oral and maxillofacial region [J]. Strahlenther Onkol, 2013,189(6):502-507.
doi: 10.1007/s00066-013-0324-3
[9] Takagi M, Demizu Y, Hashimoto N , et al. Treatment outcomes of particle radiotherapy using protons or carbon ions as a single-modality therapy for adenoid cystic carcinoma of the head and neck[J]. Radiother Oncol, 2014,113(3):364-370.
doi: 10.1016/j.radonc.2014.11.031 pmid: 25467004
[10] Chen AM, Bucci MK, Weinberg V , et al. Adenoid cystic carcinoma of the head and neck treated by surgery with or without post-operative radiation therapy: prognostic features of recurrence[J]. Int J Radiat Oncol Biol Phys, 2006,66(1):152-159.
doi: 10.1016/j.ijrobp.2006.04.014 pmid: 16904520
[11] Al-Mamgani A, van Rooij P, Sewnaik A , et al. Adenoid cystic carcinoma of parotid gland treated with surgery and radiotherapy: long-term outcomes, QoL assessment and review of the literature[J]. Oral Oncol, 2012,48(3):278-283.
doi: 10.1016/j.oraloncology.2011.10.014 pmid: 22093375
[12] Jensen AD, Nikoghosyan AV, Poulakis M , et al. Combined intensity-modulated radiotherapy plus raster-scanned carbon ion boost for advanced adenoid cystic carcinoma of the head and neck results in superior locoregional control and overall survival[J]. Cancer, 2015,121(17):3001-3009.
doi: 10.1002/cncr.29443 pmid: 26043145
[13] Casler JD, Conley JJ . Surgical management of adenoid cystic carcinoma in the parotid gland[J]. Otolaryngol Head Neck Surg, 1992,106(4):332-338.
doi: 10.1177/019459989210600403 pmid: 1314372
[14] Iseli TA, Karnell LH, Preston TW , et al. Facial nerve sacrifice and radiotherapy in parotid adenoid cystic carcinoma[J]. Laryngoscope, 2008,118(10):1781-1786.
doi: 10.1097/MLG.0b013e31817fae29 pmid: 18758382
[15] Iseli TA, Karnell LH, Graham SM , et al. Role of radiotherapy in adenoid cystic carcinoma of the head and neck[J]. J Laryngol Otol, 2009,123(10):1137-1144.
doi: 10.1017/S0022215109990338 pmid: 19573256
[16] van Weert S, Bloemena E, van der Waal I , et al. Adenoid cystic carcinoma of the head and neck: a single-center analysis of 105 consecutive cases over a 30-year period[J]. Oral Oncol, 2013,49(8):824-829.
doi: 10.1016/j.oraloncology.2013.05.004 pmid: 23751614
[17] Zheng L, Zhang JG, Zhang J , et al. Preliminary results of 125I interstitial brachytherapy for locally recurrent parotid gland cancer in previously irradiated patients [J]. Head Neck, 2012,34(10):1445-1449.
doi: 10.1002/hed.21955
[18] Zheng L, Zhang JG, Song TL , et al. 125I seed implant brachythe-rapy for the treatment of parotid gland cancers in children and adolescents [J]. Strahlenther Onkol, 2013,189(5):401-406.
doi: 10.1007/s00066-013-0313-6 pmid: 23519359
[19] 郭华秋, 刘树铭, 张杰 , 等. 老年头颈癌患者 125I粒子植入治疗后的生存质量研究 [J]. 中华放射医学与防护杂志, 2013,33(5):501-504.
doi: 10.3760/cma.j.issn.0254-5098.2013.05.011
[20] Lloyd S, Yu JB, Wilson LD , et al. Determinants and patterns of survival in adenoid cystic carcinoma of the head and neck, including an analysis of adjuvant radiation therapy[J]. Am J Clin Oncol, 2011,34(1):76-81.
doi: 10.1097/COC.0b013e3181d26d45
[21] 农晓琳, 陈琦, 黎燕宁 , 等. 63例涎腺腺样囊性癌患者预后相关因素的Cox模型分析[J]. 口腔医学, 2011,31(1):1-4.
[1] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[2] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[3] Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG. Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 661-666.
[4] Fan SHU,Yichang HAO,Zhanyi ZHANG,Shaohui DENG,Hongxian ZHANG,Lei LIU,Guoliang WANG,Xiaojun TIAN,Lei ZHAO,Lulin MA,Shudong ZHANG. Functional and oncologic outcomes of partial nephrectomy for cystic renal cell carcinoma: A single-center retrospective study [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 667-672.
[5] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[6] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[7] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[8] Junqi SU,Xiaoying WANG,Zhiqiang SUN. Establishment and verification of a prognostic nomogram for survival of tongue squamous cell carcinoma patients who underwent cervical dissection [J]. Journal of Peking University (Health Sciences), 2024, 56(1): 120-130.
[9] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[10] Yun-chong LIU,Zong-long WU,Li-yuan GE,Tan DU,Ya-qian WU,Yi-meng SONG,Cheng LIU,Lu-lin MA. Mechanism of nuclear protein 1 in the resistance to axitinib in clear cell renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 781-792.
[11] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[12] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[13] Dong LAN,Zhuo LIU,Yu-xuan LI,Guo-liang WANG,Xiao-jun TIAN,Lu-lin MA,Shu-dong ZHANG,Hong-xian ZHANG. Risk factors for massive hemorrhage after radical nephrectomy and removal of venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 825-832.
[14] Yu-xiao WU,Yi-fan KANG,Qian-ying MAO,Zi-meng LI,Xiao-feng SHAN,Zhi-gang CAI. Application of methylene blue near-infrared fluorescence imaging for oral sentinel lymph node mapping in rats [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 684-688.
[15] Shang XIE,Zhi-gang CAI,Xiao-feng SHAN. Application value of whole exon sequencing and immune related indicators in the precision treatment of oral squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 697-701.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd